| BID | 5.26 | ASK | 5.27 | ||
| Open | 5.44 | Previous Close | 5.66 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 14.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 171.92 | Finscreener Ranking | ★★★ 51.01 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 46.83 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 44.95 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 1.47B | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 32.16 | Earnings Date | 23rd Mar 2021 |
Today's Price Range 5.125.70 | 52W Range 0.330015.69 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -23.51% | ||
| 1 Month | -41.64% | ||
| 3 Months | -34.53% | ||
| 6 Months | 853.16% | ||
| 1 Year | 1 411.43% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 421.39 | |||
ROE last 12 Months | -210.71 | |||
ROA (5Y Avg) | -59.52 | |||
ROA last 12 Months | -88.08 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -164.45 | |||
Return on invested Capital Q | -32.78 | |||
Return on invested Capital Y | -110.08 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.90 | ||||
| 44.96 | ||||
| 199.34 | ||||
| - | ||||
| -48.20 | ||||
| -0.37 | ||||
| 59.66 | ||||
| 0.13 | ||||
| 1.56B | ||||
| Forward PE | -23.58 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.60 | ||||
| 5.20 | ||||
| 0.32 | ||||
| 0.47 | ||||
| -15.30 | ||||
| Leverage Ratio | 2.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 32.60 | ||||
| -474.40 | ||||
| -457.70 | ||||
| -288.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.37M | ||||
| 0.03 | ||||
| -5.05 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.06 | -0.06 | 0.00 |
| Q03 2020 | -0.06 | -0.08 | -33.33 |
| Q02 2020 | -0.09 | -0.09 | 0.00 |
| Q01 2020 | -0.22 | -0.30 | -36.36 |
| Q03 2019 | -0.57 | -0.59 | -3.51 |
| Q02 2019 | -0.57 | -0.71 | -24.56 |
| Q01 2019 | -0.56 | -0.68 | -21.43 |
| Q04 2018 | -0.48 | -0.62 | -29.17 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.05 | 28.57 | Positive |
| 6/2021 QR | -0.05 | 28.57 | Positive |
| 12/2021 FY | -0.19 | 13.64 | Positive |
| 12/2022 FY | -0.24 | -26.32 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.05 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 18.63M |
| Shares Outstanding | 278.66M |
| Trades Count | 74.72K |
| Dollar Volume | 236.84M |
| Avg. Volume | 58.96M |
| Avg. Weekly Volume | 20.07M |
| Avg. Monthly Volume | 17.91M |
| Avg. Quarterly Volume | 35.69M |
Bionano Genomics Inc. (NASDAQ: BNGO) stock closed at 5.27 per share at the end of the most recent trading day (a -6.89% change compared to the prior day closing price) with a volume of 18.81M shares and market capitalization of 1.47B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 97 people. Bionano Genomics Inc. CEO is Mark Adamchak.
The one-year performance of Bionano Genomics Inc. stock is 1411.43%, while year-to-date (YTD) performance is 71.1%. BNGO stock has a five-year performance of %. Its 52-week range is between 0.33 and 15.69, which gives BNGO stock a 52-week price range ratio of 32.16%
Bionano Genomics Inc. currently has a PE ratio of -10.90, a price-to-book (PB) ratio of 44.96, a price-to-sale (PS) ratio of 199.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -88.08%, a ROC of -164.45% and a ROE of -210.71%. The company’s profit margin is -%, its EBITDA margin is -457.70%, and its revenue ttm is $7.37 Million , which makes it $0.03 revenue per share.
Of the last four earnings reports from Bionano Genomics Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Bionano Genomics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bionano Genomics Inc. is Strong Buy (1), with a target price of $14.33, which is +171.92% compared to the current price. The earnings rating for Bionano Genomics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bionano Genomics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bionano Genomics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 26.19, ATR14 : 1.23, CCI20 : -194.90, Chaikin Money Flow : -0.23, MACD : -1.18, Money Flow Index : 24.16, ROC : -34.78, RSI : 38.99, STOCH (14,3) : 4.53, STOCH RSI : 0.00, UO : 33.09, Williams %R : -95.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bionano Genomics Inc. in the last 12-months were:
Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
CEO: Mark Adamchak
Telephone: +1 858 888-7600
Address: 9540 Towne Centre Drive, San Diego 92121, CA, US
Number of employees: 97
